Published in Biotech Business Week, October 13th, 2003
Phenserine is a dual action acetylcholinesterase and beta amyloid precursor protein (B-APP) inhibitor currently in clinical development for the treatment of mild-to-moderate AD.
All patients that have completed the previously announced and ongoing 75 patient phase IIB and the 375 patient phase III clinical trials will be given the opportunity to receive 6 months of Phenserine treatment in an open-label extension...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.